Abstract: Objective To explore the diagnostic value of pepsinogen Ⅰ (PG Ⅰ) and pepsin Ⅱ (PG Ⅱ) in the screening for gastric cancer. Methods 15 patients with gastric cancer, 20 patients with atrophic gastritis, 23 cases of gastric ulcer patients, 25 cases of superficial gastritis patients and 80 healthy physical examination personnel were selected in this study. The PG Ⅰ and PG Ⅱ content were detected by using latex enhanced immune transmission turbidimetry. Results The PG Ⅰ content in gastric cancer patients, patients with atrophic gastritis, gastric ulcer patients, superficial gastritis patients and physical examination personnel were 37.13 ±18.59 ng/ml, 39.27 ± 16.29 ng/mL, 180.42 ± 61.27 ng/mL, 128.12 ±14.65 ng/mL and 120.19 ± 16.96 ng/mL respectively. The PG I in patients with gastric cancer and atrophic gastritis group were significantly lower than that of normal controls (P < 0.05). The PG Ⅱcontent in gastric cancer patients, patients with atrophic gastritis, gastric ulcer patients, superficial gastritis patients and physical examination personnel were 20.67 ±9.59 ng/mL, 16.35 ±16.89 ng/mL, 22.95 ±13.46 ng/mL, 8.05 ± 4.04 ng/ml, and 11.85 ±9.65 ng/mL respectively. There was no significant difference between each groups (P>0.05). The positive rate of PG Ⅰ and PG Ⅱ in patients with gastric cancer and atrophic gastritis group were significantly higher than other groups (P < 0.05). Conclusion The detection of PG Ⅰ and PG Ⅱcould provide significant value in the gastric cancer and atrophic gastritis disease screening and diagnosis.